Eli Lilly to invest $3bn in China in anticipation of orforglipron approval

Core Insights - Eli Lilly is investing $3 billion to expand its supply chain capacity in China for the oral weight loss drug orforglipron, with a focus on meeting future demand [1] - The company has submitted an application for orforglipron for treating type 2 diabetes and obesity to China's National Medical Products Administration, expected by the end of 2025 [1] Investment and Expansion - The investment will enhance existing facilities and establish collaborations, including a $200 million partnership with Pharmaron, a Chinese CDMO [2] - Lilly's Suzhou manufacturing site, established in 1996, is undergoing a major expansion following a $212 million investment in October 2024 to increase production for diabetes and obesity medications [3] Strategic Commitment - Lilly's total investment in China has reached nearly $6 billion, reflecting a long-term strategy to maintain orforglipron production globally [4] - In February 2025, Lilly announced plans for four new manufacturing facilities in the US as part of a $27 billion investment, with at least three confirmed for weight loss therapies [4] Product Performance and Market Forecast - Orforglipron, a once-daily oral GLP-1 receptor agonist, showed a weight loss of 12.4% over 72 weeks in overweight adults during a Phase III trial [5] - GlobalData forecasts that orforglipron could generate $13 billion in global sales by 2031 if approved, prompting Lilly to prepare for significant supply chain demands [6] - Lilly reported a 45% surge in 2025 revenue, driven by sales of Zepbound and Mounjaro, amounting to $13.5 billion and $23 billion, respectively [6]